Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine

作者：Jianhua Yin, Yingze Zhao, Fubaoqian Huang, Yunkai Yang, Yaling Huang, Zhenkun Zhuang, Yanxia Wang, Zhifeng Wang, Xiumei Lin, Yuhui Zheng, Wenwen Zhou, Shuo Wang, Ziqian Xu, Beiwei Ye, Yaxin Guo, Wenwen Lei, Lei Li, Jinmin Tian, Jinxian Gan, Hui Wang, Wei Wang, Peiyao Ma, Chang Liu, Chang Liu, Xuyang Shi, Xuyang Shi, Yang Wang, Yang Wang, Ying Liu, M. Yang, Yi Yuan, Yumo Song, Wen Ma, Zhuoli Huang, Ya Liu, Y Huang, Peipei Liu, Peipei Liu, Hao Liang, Yong Hou, X X Xu, Longqi Liu, Yuntao Zhang, Guizhen Wu, Gao G, Xin Jin, Chuanyu Liu, William J. Liu, Xiaoming Yang, William J. Liu · 发表于：The Innovation · 年份：2022 · DOI：10.1016/j.xinn.2022.100359 · 被引用次数：20 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Immune responses and vaccinations

The BBIBP-CorV severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccine has been authorized for emergency use and widely distributed. We used single-cell transcriptome sequencing to characterize the dynamics of immune responses to the BBIBP-CorV inactivated vaccine. In addition to the expected induction of humoral immunity, we found that the inactivated vaccine induced multiple, comprehensive immune responses, including significantly increased proportions of CD16 + monocytes and activation of monocyte antigen presentation pathways; T cell activation pathway upregulation in CD8 + T cells, along with increased activation of CD4 + T cells; significant enhancement of cell-cell communications between innate and adaptive immunity; and the induction of regulatory CD4 + T cells and co-inhibitory interactions to maintain immune homeostasis after vaccination. Additionally, comparative analysis revealed higher neutralizing antibody levels, distinct expansion of naive T cells, a shared increased proportion of regulatory CD4 + T cells, and upregulated expression of functional genes in booster dose recipients with a longer interval after the second vaccination. Our research will support a comprehensive understanding of the systemic immune responses elicited by the BBIBP-CorV inactivated vaccine, which will facilitate the formulation of better vaccination strategies and the design of new vaccines.